Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 8/20 | 0.46 |
| ▸ | BCHE | P06276 | 6/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | CACNB4 | O00305 | 1/20 | 0.46 |
| ▸ | CACNA1A | O00555 | 1/20 | 0.46 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.46 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.46 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.46 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.46 |
| ▸ | CACNG3 | O60359 | 1/20 | 0.46 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.46 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.46 |
| ▸ | APP | P05067 | 1/20 | 0.46 |
| ▸ | FABP1 | P07148 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29374271 | 1.00 | ACHE (0.46) | ACHEBCHEALDH1A1TSHRHSD17B10 | |
| SCHEMBL8088682 | 0.96 | ACHE (0.46) | ACHEBCHEALDH1A1TSHRHSD17B10 | |
| Perchlorate SCHEMBL3915050 | 0.90 | ACHE (0.40) | ACHEBCHEALDH1A1TSHRHSD17B10 | |
| SCHEMBL18576434 | 0.88 | KDM4E (0.47) | ACHEBCHEALDH1A1TSHRHSD17B10 | |
| SCHEMBL726973 | 0.75 | KDM4E (0.39) | KDM4EGPR3TDP1 | |
| SCHEMBL637592 | 0.73 | KDM4E (0.40) | ACHEBCHEALDH1A1TSHRHSD17B10 | |
| SCHEMBL7901264 | 0.72 | KDM4E (0.39) | ACHEBCHEALDH1A1TSHRHSD17B10 | |
| SCHEMBL10379077 | 0.72 | UHRF1 (0.40) | BCHEALDH1A1HSD17B10KDM4ECYP1A2 | |
| SCHEMBL22235250 | 0.72 | HSD17B10 (0.42) | ACHEBCHEALDH1A1HSD17B10KDM4E | |
| SCHEMBL15647796 | 0.72 | ATM (0.40) | ACHEBCHEALDH1A1TSHRHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 521 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115028581-A | Preparation method of hydrogenated phenanthridine derivatives and application of hydrogenated phenanthridine derivatives in preparation of antitumor drugs | 常州大学 | 2022-09-09 | — | — | CN | claimed |
| US-20260146047-A1 | MACROCYCLIC HETEROCYCLE COMPOUNDS AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2026-05-28 | — | — | US | disclosed |
| US-12637418-B2 | Heterocyclic compounds as antagonist of NMDA | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2026-05-26 | — | — | US | disclosed |
| CN-122071471-A | Heterocyclic compounds | 武田药品工业株式会社 | 2026-05-22 | — | — | CN | disclosed |
| US-12630534-B2 | 1-((1H-pyrazol-4-yl)methyl)-3-(phenyl)-1,3-dihydro-2H-imidazol-2-one derivatives and related compounds as GPR139 antagonists for the treatment of e.g. depression | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2026-05-19 | — | — | US | disclosed |
| EP-3617208-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2026-05-13 | — | — | EP | disclosed |
| CN-122010946-A | Heterocyclic compounds | 武田药品工业株式会社 | 2026-05-12 | — | — | CN | disclosed |
| CN-122010945-A | Heterocyclic compounds | 武田药品工业株式会社 | 2026-05-12 | — | — | CN | disclosed |
| US-20260092033-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2026-04-02 | — | — | US | disclosed |
| US-12590086-B2 | 3-((1H-pyrazol-4-yl)methyl)-6′-(phenyl)-2H-(1,2′-bipyridin)-2-one derivatives and related compounds as GPR139 antagonists for use in a method of treatment of e.g. depression | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2026-03-31 | — | — | US | disclosed |
| EP-1283199-A1 | MELANIN-CONCENTRATING HORMONE ANTAGONIST | Takeda Chemical Industries, Ltd. (JP) | 2003-02-12 | — | — | EP | disclosed |
| EP-1218336-A2 | MELANIN CONCENTRATING HORMONE ANTAGONIST | Takeda Chemical Industries, Ltd. (JP) | 2002-07-03 | — | — | EP | disclosed |
| WO-2001021577-A2 | MELANIN CONCENTRATING HORMONE ANTAGONIST | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-03-29 | — | — | WO | disclosed |
| US-5527805-A | DNA-CLEAVING, CYTOTOXIC AND ANTI-TUMOR COMPOUNDS | THE SCRIPPS RESEARCH INSTITUTE (US) | 1996-06-18 | — | — | US | disclosed |
| EP-0594624-A1 | DYNEMICIN ANALOGS: SYNTHESES, METHODS OF PREPARATION AND USE | SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) | 1994-05-04 | — | — | EP | disclosed |
| EP-0594624-A4 | DYNEMICIN ANALOGS: SYNTHESES, METHODS OF PREPARATION AND USE. | SCRIPPS CLINIC RES (US) | 1994-02-21 | — | — | EP | disclosed |
| US-5281710-A | Antibiotics or antitumor agents | THE SCRIPPS RESEARCH INSTITUTE (US) | 1994-01-25 | — | — | US | disclosed |
| US-5276159-A | Antitumor | THE SCRIPPS RESEARCH INSTITUTE (US) | 1994-01-04 | — | — | US | disclosed |
| WO-1992002522-A1 | DYNEMICIN ANALOGS: SYNTHESES, METHODS OF PREPARATION AND USE | SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) | 1992-02-20 | — | — | WO | disclosed |
| US-4081543-A | ANTIAGRESSIVE, CENTRAL NERVOUS SYSTEM DEPRESSANTS | SANDOZ LTD. (CH) | 1978-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260092033-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | HCRTR2, HCRTR1, MTNR1B | ACHE 2739/4885BCHE 745/4885ALDH1A1 1588/4885 |
| US-12590086-B2 | 3-((1H-pyrazol-4-yl)methyl)-6′-(phenyl)-2H-(1,2′-bipyridin)-2-one derivatives and related compounds as GPR139 antagonists for use in a method of treatment of e.g. depression | GPR139, OPRL1, GRIN2C | ACHE 229/4885BCHE 694/4885ALDH1A1 1460/4885 |
| US-12637418-B2 | Heterocyclic compounds as antagonist of NMDA | GRIN1, GRIN3A, GRIN2A | ACHE 690/4885BCHE 837/4885ALDH1A1 2319/4885 |
| US-20260146047-A1 | MACROCYCLIC HETEROCYCLE COMPOUNDS AND USE THEREOF | HCRTR2, HCRTR1, NPY1R | ACHE 3754/4885BCHE 1795/4885ALDH1A1 3220/4885 |
| US-12630534-B2 | 1-((1H-pyrazol-4-yl)methyl)-3-(phenyl)-1,3-dihydro-2H-imidazol-2-one derivatives and related compounds as GPR139 antagonists for the treatment of e.g. depression | GPR139, OPRL1, GRIN2C | ACHE 291/4885BCHE 911/4885ALDH1A1 1685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.